IMR Press / FBL / Volume 28 / Issue 9 / DOI: 10.31083/j.fbl2809206
Open Access Review
Present Status and Advances in Chimeric Antigen Receptor T Cell Therapy for Glioblastoma
Shuchang Zhou1,2,†Han Sun1,2,†Sun Il Choi1,2,*Jinlong Yin1,2,*
Show Less
1 Henan Key Laboratory of Brain Targeted Bio-Nanomedicine, School of Life Sciences & School of Pharmacy, Henan University, 475004 Kaifeng, Henan, China
2 Henan-Macquarie University Joint Centre for Biomedical Innovation, School of Life Sciences, Henan University, 475004 Kaifeng, Henan, China
*Correspondence: (Sun Il Choi); (Jinlong Yin)
These authors contributed equally.
Front. Biosci. (Landmark Ed) 2023, 28(9), 206;
Submitted: 25 February 2023 | Revised: 4 April 2023 | Accepted: 7 April 2023 | Published: 15 September 2023
Copyright: © 2023 The Author(s). Published by IMR Press.
This is an open access article under the CC BY 4.0 license.

Adoptive chimeric antigen receptor (CAR) T cells designed to recognize specific tumor antigens have shown promising results in cancer therapy. While CAR T cell therapy has demonstrated notable clinical effectiveness for hematologic disease, efforts to develop therapies for solid tumors, including glioblastoma (GBM), have been hampered by heterogeneity, an immunosuppressive tumor microenvironment, and difficulty in trafficking. Several specific tumor antigens, such as IL13Rα2, EGFRvIII, and HER2, have been attempted in clinical trials; however, limited efficacy has been observed. In this review, we discuss the current status of CAR T therapy for GBM in clinical trials and highlight the potential target antigens for CAR T cells. Additionally, we summarize the mechanisms used to enhance their efficacy and explore the challenges and future prospects of CAR T cell therapy for GBM.

cancer therapy
cell therapy
82173228/National Natural Science Foundation of China
Fig. 1.
Back to top